Benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a disease mainly caused by the disorder of sex hormone metabolism in the elderly, which leads to the proliferation of glands and (or) fibers and muscle tissues to varying degrees, resulting in an increase in the size of the prostate, destruction of normal structure and a series of functional disorders. Benign prostatic hyperplasia is a common disease in middle-aged and elderly men, and about half of men over 50 years old will have clinical symptoms. The enlarged prostate squeezes the urethra, leading to a series of urination disorders, such as frequent urination, urgency, weak urine flow, and incomplete urination. These symptoms seriously affect the patient's quality of life. Failure to treat them in time can lead to many serious complications (such as acute urinary retention, stones, renal insufficiency, etc.), and may even endanger the patient's life.
Related Drugs
Terazosin Hydrochloride
Indication: It is used to treat mild or moderate hypertension. It can be used alone or in combination with other antihypertensive drugs such as thiazide diuretics or beta-blockers. It is used to relieve obstructive symptoms of benign prostatic hyperplasia (BPH).
Finasteride Tablets
Indication: This product is suitable for the treatment of benign prostatic hyperplasia and can shrink the enlarged prostate; improve urine flow and the comprehensive complications caused by prostatic hyperplasia; reduce the risk of acute urinary retention and the risk of prostatectomy.
Manufacturer:
Liaoning Yuhuang Pharmaceutical Co., Ltd.
Finasteride Tablets
Indication: Finasteride tablets are 5-alpha reductase inhibitors and are the most commonly used drugs for the treatment of benign prostatic hyperplasia (BPH). They reduce the size of the prostate, relieve symptoms, increase urine flow rate, and delay disease progression through hormone regulation mechanisms.
Manufacturer:
Beijing Hanmi Pharmaceutical Co., Ltd.
Terazosin Hydrochloride Capsules
Indication: 1. Used to treat hypertension, and can be used alone or in combination with other antihypertensive drugs. 2. Used to improve urination symptoms in patients with benign prostatic hyperplasia, such as frequent urination, urgency, thinning of the urine stream, difficulty urinating, increased nocturia, and a feeling of incomplete urination.
Manufacturer:
Qilu Pharmaceutical Co., Ltd.
Finasteride capsules
Indication: This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). ————Improve symptoms; ————Reduce the risk of acute urinary retention; ————Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Manufacturer:
Sichuan Mingxing Pharmaceutical Co., Ltd.
Finasteride capsules
Indication: This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). ————Improve symptoms; ————Reduce the risk of acute urinary retention; ————Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Manufacturer:
Shenyang Minghua Pharmaceutical Co., Ltd.
Finasteride capsules
Indication: This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). ————Improve symptoms; ————Reduce the risk of acute urinary retention; ————Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Manufacturer:
Wuhan Humanwell Pharmaceutical Co., Ltd.
Finasteride capsules
Indication: This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). ————Improve symptoms; ————Reduce the risk of acute urinary retention; ————Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Manufacturer:
Jiangsu Xiangrui Pharmaceutical Co., Ltd.
Finasteride capsules
Indication: This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). ————Improve symptoms; ————Reduce the risk of acute urinary retention; ————Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Manufacturer:
Shandong Zibo Xinda Pharmaceutical Co., Ltd.